Agonist and blocking actions of choline and tetramethylammonium on human muscle acetylcholine receptors.
Choline has been used widely as an agonist for the investigation of gain-of-function mutants of the nicotinic acetylcholine receptor. It is useful because it behaves like a partial agonist. The efficacy of choline is difficult to measure because choline blocks the channel at concentrations about four times lower than those that activate it. We have fitted activation mechanisms to single-channel activity elicited from HEK-expressed human recombinant muscle nicotinic receptors by choline and by tetramethylammonium (TMA). Channel block by the agonist was incorporated into the mechanisms that were fitted, and block was found not to be selective for the open state. The results also suggest that channel block is very fast and that the channel can shut almost as fast as normal when the blocker was bound. Single-channel data are compatible with a mechanism in which choline is actually a full agonist, its maximum response being limited only by channel block. However, they are also compatible with a mechanism incorporating a pre-opening conformation change ('flip') in which choline is a genuine partial agonist. The latter explanation is favoured by concentration jump experiments, and by the fact that only this mechanism fits the TMA data. We propose that choline, like TMA, is a partial agonist because it is very ineffective (approximately 600-fold less than acetylcholine) at eliciting the initial, pre-opening conformation change. Once flipping has occurred, all agonists, even choline, open the channel with similar efficiency.
Lape
Remigijus
R
Department of Neuroscience, Physiology and Pharmacology, Medical Sciences Building, University College London, Gower St, London WC1E 6BT, UK.
Krashia
Paraskevi
P
Colquhoun
David
D
Sivilotti
Lucia G
LG
D002460:Cell Line; D002794:Choline / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects / Q000502:physiology*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000378:metabolism*; D018722:Nicotinic Agonists / Q000008:administration & dosage; D018733:Nicotinic Antagonists / Q000008:administration & dosage; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage*; D011978:Receptors, Nicotinic / Q000187:drug effects* / Q000378:metabolism*
D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D000644:Quaternary Ammonium Compounds; D011978:Receptors, Nicotinic; C027917:tetramethylammonium; D002794:Choline